InvestorsHub Logo
Followers 0
Posts 5690
Boards Moderated 0
Alias Born 06/09/2012

Re: Bolio98 post# 102163

Friday, 03/10/2017 1:49:32 PM

Friday, March 10, 2017 1:49:32 PM

Post# of 428287
Interesting development today with the Epanova label. Could be bearish. Well these are the risks to spec biotech investing. Something can come out of left field and significantly hurt your position that you'd never have expected.

I don't know why anyone is bothering with bios when energy stocks are extremely oversold. It's a gold mine out there in the energy sector. I'm almost completely out of bios at this point.

As to your comment, I'll just quote a lipidologist:

"The entire premise behind developing vascepa and their entire marketing plan depends on a fallacy that any lipidologist understands but sadly few internists appreciate. It does not matter if LDL C is elevated with lovaza as long as apoB or LDL P or particle number is lowered by fish oils. Remnant lipoproteins, size density and # of atherogenic particles are nicely controlled by lovaza so the success of vascepa in the marketplace depends on the prevalence of ignorant docs who care about LDL C and have never ordered advanced testing. Amarin apparently believes its own nonsense and is living a lie. I hate products that look worse the more you understand the field… Vascepa falls apart on scrutiny and appeals only to dumb docs."

Maybe he's just a crabby guy, but makes sense to me. Even docs just don't look deep enough much of the time. They're simply too busy.

Cheers and gotta run

"Think for yourselves and let others enjoy the privilege to do so, too."

-Voltaire

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News